PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

Phase 2

Completed

Conditions: Palliative Care
Neoplasm Metastasis

Interventions: Drug: Tanezumab 10 mg IV
Drug: IV Placebo for tanezumab

First Posted Date: 2007-10-17

Last Posted Date: 2021-06-18

Lead Sponsor: Pfizer

Target Recruit Count: 59

Registration Number: NCT00545129

Locations: 🇱🇻
10th Department, Latvian Oncological Centre / Riga Eastern Clinical University Hospital, Riga, Latvia
🇮🇳
Shatabdi Superspeciality Hospital, Nashik, Maharashtra, India
🇸🇰
Narodny onkologicky ustav, Bratislava, Slovakia

and more 36 locations

Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Etanercept

First Posted Date: 2007-10-16

Last Posted Date: 2015-05-12

Lead Sponsor: Pfizer

Target Recruit Count: 1715

Registration Number: NCT00544557

Locations: 🇩🇪
Klinikum Benjamin Franklin, Berlin, Germany

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Biological: Moroctocog alfa (AF-CC)

First Posted Date: 2007-10-15

Last Posted Date: 2019-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00543439

Locations: 🇹🇷
Istanbul Universtesi Istanbul Tip Fakultesi, Capa, Istanbul, Turkey
🇷🇴
Sanador, Bucuresti, Romania
🇹🇷
Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey

and more 25 locations

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: PD 0332334
Drug: Placebo

First Posted Date: 2007-10-11

Last Posted Date: 2012-11-16

Lead Sponsor: Pfizer

Target Recruit Count: 551

Registration Number: NCT00542685

Locations: 🇺🇸
Pfizer Investigational Site, Middleton, Wisconsin, United States

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

Phase 2

Completed

Conditions: Dental Pain

Interventions: Drug: Placebo; oral
Drug: ARRY-371797, p38 inhibitor; oral

First Posted Date: 2007-10-10

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 103

Registration Number: NCT00542035

Locations: 🇺🇸
SCIREX Research Center, Salt Lake City, Utah, United States

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

Phase 2

Completed

Conditions: Weight Management
Treatment Of Obesity

Interventions: Drug: CE-326,597 100 mg QD
Drug: CE-326,597 50 mg QD
Drug: CE-326,597 25 mg QD
Drug: Placebo
Drug: CE-326,597 5mg QD

First Posted Date: 2007-10-10

Last Posted Date: 2012-11-07

Lead Sponsor: Pfizer

Target Recruit Count: 252

Registration Number: NCT00542009

Locations: 🇪🇸
Pfizer Investigational Site, Sevilla, Spain

An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers

Phase 1

Completed

Conditions: Generalized Anxiety Disorder

First Posted Date: 2007-10-01

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT00537615

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Anidulafungin In Treatment Of Candidemia In Asian Subjects

Phase 3

Completed

Conditions: Candidemia

Interventions: Drug: Anidulafungin

First Posted Date: 2007-10-01

Last Posted Date: 2010-03-09

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00537329

Locations: 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Khon Kaen, Thailand

Fesoterodine Flexible Dose Study

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Placebo
Drug: Fesoterodine

First Posted Date: 2007-09-27

Last Posted Date: 2009-09-15

Lead Sponsor: Pfizer

Target Recruit Count: 896

Registration Number: NCT00536484

Locations: 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States

ACTiF- Assessment of Closed Tibial Fractures

Phase 2

Completed

Conditions: Tibial Fractures

Interventions: Drug: CP-533, 536
Drug: Placebo
Procedure: Standard of Care
Drug: CP-533,536

First Posted Date: 2007-09-21

Last Posted Date: 2012-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 276

Registration Number: NCT00533377

Locations: 🇹🇷
Pfizer Investigational Site, Izmir, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy